Clifford Swan Investment Counsel’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11M Sell
458,641
-30,654
-6% -$802K 0.35% 80
2026
Q1
$13.7M Buy
489,295
+3,745
+0.8% +$99.7K 0.47% 64
2025
Q4
$12.1M Sell
485,550
-17,164
-3% -$433K 0.4% 70
2025
Q3
$12.8M Sell
502,714
-66,458
-12% -$1.64M 0.43% 68
2025
Q2
$13.8M Sell
569,172
-27,572
-5% -$643K 0.49% 64
2025
Q1
$15.1M Sell
596,744
-4,880
-0.8% -$128K 0.56% 56
2024
Q4
$16M Buy
601,624
+47,279
+9% +$1.28M 0.57% 56
2024
Q3
$16M Buy
554,345
+34,555
+7% +$1.01M 0.57% 57
2024
Q2
$14.5M Buy
519,790
+2,935
+0.6% +$80.8K 0.54% 56
2024
Q1
$14.3M Buy
516,855
+99,785
+24% +$2.77M 0.53% 60
2023
Q4
$12M Buy
417,070
+18,611
+5% +$563K 0.47% 68
2023
Q3
$13.2M Buy
398,459
+982
+0.2% +$34.7K 0.55% 57
2023
Q2
$14.6M Sell
397,477
-2,018
-0.5% -$78.5K 0.59% 56
2023
Q1
$16.3M Sell
399,495
-6,495
-2% -$281K 0.68% 49
2022
Q4
$20.8M Sell
405,990
-646
-0.2% -$31K 0.91% 34
2022
Q3
$17.8M Sell
406,636
-6,065
-1% -$295K 0.84% 39
2022
Q2
$21.6M Sell
412,701
-7,567
-2% -$386K 0.94% 32
2022
Q1
$21.8M Buy
420,268
+492
+0.1% +$25.5K 0.81% 39
2021
Q4
$24.8M Sell
419,776
-1,378
-0.3% -$68.3K 0.87% 35
2021
Q3
$18.4M Sell
421,154
-23,249
-5% -$1.03M 0.67% 42
2021
Q2
$20.1M Sell
444,403
-26,462
-6% -$1.03M 0.76% 39
2021
Q1
$17.1M Buy
470,865
+26,831
+6% +$953K 0.7% 43
2020
Q4
$16.3M Sell
444,034
-35,861
-7% -$1.32M 0.71% 44
2020
Q3
$16.7M Sell
479,895
-4,148
-0.9% -$145K 0.8% 39
2020
Q2
$15M Sell
484,043
-6,288
-1% -$214K 0.77% 41
2020
Q1
$15.2M Buy
490,331
+1,501
+0.3% +$51.1K 0.92% 35
2019
Q4
$18.2M Sell
488,830
-962
-0.2% -$34.3K 0.88% 37
2019
Q3
$16.7M Buy
489,792
+11,960
+3% +$435K 0.87% 39
2019
Q2
$19.6M Sell
477,832
-4,169
-0.9% -$166K 1.03% 31
2019
Q1
$19.4M Sell
482,001
-9,102
-2% -$365K 1.04% 32
2018
Q4
$20.3M Sell
491,103
-28,800
-6% -$1.2M 1.23% 24
2018
Q3
$21.7M Sell
519,903
-10,740
-2% -$413K 1.13% 27
2018
Q2
$18.3M Sell
530,643
-6,675
-1% -$228K 1.02% 33
2018
Q1
$18.1M Buy
537,318
+32,862
+7% +$1.13M 1.02% 31
2017
Q4
$17.3M Sell
504,456
-11,380
-2% -$388K 0.94% 36
2017
Q3
$17.5M Sell
515,836
-1,106
-0.2% -$35.5K 1.06% 28
2017
Q2
$16.5M Sell
516,942
-13,329
-3% -$420K 1.03% 29
2017
Q1
$17.2M Sell
530,271
-10,275
-2% -$324K 1.1% 27
2016
Q4
$16.7M Buy
540,546
+21,044
+4% +$642K 1.11% 27
2016
Q3
$16.7M Buy
519,502
+1,509
+0.3% +$50.5K 1.13% 27
2016
Q2
$17.3M Sell
517,993
-16,186
-3% -$517K 1.2% 22
2016
Q1
$15M Sell
534,179
-18,484
-3% -$528K 1.02% 32
2015
Q4
$16.9M Buy
552,663
+2,235
+0.4% +$70.3K 1.16% 26
2015
Q3
$16.4M Sell
550,428
-2,662
-0.5% -$85.4K 1.17% 27
2015
Q2
$17.6M Sell
553,090
-8,660
-2% -$282K 1.18% 29
2015
Q1
$18.5M Sell
561,750
-22,205
-4% -$706K 1.22% 25
2014
Q4
$17.3M Sell
583,955
-8,376
-1% -$240K 1.14% 32
2014
Q3
$16.6M Sell
592,331
-8,558
-1% -$240K 1.13% 31
2014
Q2
$16.9M Sell
600,889
-20,586
-3% -$587K 1.14% 32
2014
Q1
$18.9M Buy
621,475
+2,399
+0.4% +$71.5K 1.33% 25
2013
Q4
$18M Sell
619,076
-11,092
-2% -$323K 1.3% 28
2013
Q3
$17.2M Buy
630,168
+29,558
+5% +$804K 1.37% 25
2013
Q2
$16M Buy
+600,610
New +$16.6M 1.33% 26

Other funds holding PFE

Clifford Swan Investment Counsel's PFE Position: Q2 2026 in Review

Clifford Swan Investment Counsel reduced its Pfizer (PFE) stake by 6.3% in Q2 2026, selling an estimated $802K and leaving 458,641 shares worth $11M. The position accounts for 0.35% of the portfolio, ranked #80.

Clifford Swan Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $24.8M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Clifford Swan Investment Counsel held 458,641 shares of Pfizer worth $11M as of Q2 2026.
  • Clifford Swan Investment Counsel sold 30,654 Pfizer shares in Q2 2026, an estimated $802K.
  • Pfizer made up 0.35% of Clifford Swan Investment Counsel's portfolio in Q2 2026, its #80 holding.
  • Clifford Swan Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Clifford Swan Investment Counsel's Pfizer position peaked at $24.8M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Clifford Swan Investment Counsel's 13F filing for Q2 2026, filed 20 Aug 2026.